Advanced search
Start date
Betweenand


Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and l-DOPA-Induced Dyskinesia

Full text
Author(s):
Ferreira Junior, Nilson Carlos ; dos-Santos-Pereira, Mauricio ; Guimaraes, Francisco Silveira ; Del Bel, Elaine
Total Authors: 4
Document type: Journal article
Source: NEUROTOXICITY RESEARCH; v. 37, n. 1, p. 18-pg., 2019-10-22.
Abstract

Parkinson's disease (PD) and l-DOPA-induced dyskinesia (LID) are motor disorders with significant impact on the patient's quality of life. Unfortunately, pharmacological treatments that improve these disorders without causing severe side effects are not yet available. Delay in initiating l-DOPA is no longer recommended as LID development is a function of disease duration rather than cumulative l-DOPA exposure. Manipulation of the endocannabinoid system could be a promising therapy to control PD and LID symptoms. In this way, phytocannabinoids and synthetic cannabinoids, such as cannabidiol (CBD), the principal non-psychotomimetic constituent of the Cannabis sativa plant, have received considerable attention in the last decade. In this review, we present clinical and preclinical evidence suggesting CBD and other cannabinoids have therapeutic effects in PD and LID. Here, we discuss CBD pharmacology, as well as its neuroprotective effects and those of other cannabinoids. Finally, we discuss the modulation of several pro- or anti-inflammatory factors as possible mechanisms responsible for the therapeutic/neuroprotective potential of Cannabis-derived/cannabinoid synthetic compounds in motor disorders. (AU)

FAPESP's process: 17/14207-7 - The action of cannabinoid drugs in L-dopa-induced dyskinesia: analysis of neuroinflammation and glutamate release in glial cells
Grantee:Maurício dos Santos Pereira
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 12/17626-7 - Cellular and molecular mechanisms involved in the role of atypical neurotransmitters in neuropsychiatric disorders
Grantee:Francisco Silveira Guimaraes
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 14/25029-4 - Contribution of the neuroinflamation to L-DOPA induced dyskinesia
Grantee:Elaine Aparecida Del Bel Belluz Guimarães
Support Opportunities: Research Projects - Thematic Grants